StockData
ELI LILLY & Co logo

ELI LILLY & Co

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3025% above fair value
$1410.99−6.55 (-0.46%)

Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%

Eli Lilly Forteo (teriparatide) — U.S. revenue [legacy] by Year

Forteo (teriparatide) — U.S. revenue ($M) [legacy] ($M)

Eli Lilly Forteo (teriparatide) — U.S. revenue [legacy]: $336M in FY2023, down 8.7% from a year earlier. That is the lowest of the 8 years on record here. No newer figure appears in the documents we track.

Latest, FY2023
336
Period ended Dec 31, 2023
Change on a year earlier
-8.7%
367 in FY2022
History
8 years
Since FY2016
Sources
6
Documents cited below

Where the FY2023 figure comes from

Source: Form 10-K (filed 2024-02-21) ↗

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedForteo (teriparatide) — U.S. revenue ($M) [legacy] ($M)Year on yearSource
FY2023Dec 31, 2023336-8.7%Form 10-K (filed 2024-02-21) ↗
FY2022Dec 31, 2022367-16.8%Form 10-K (filed 2024-02-21) ↗
FY2021Dec 31, 2021442-13.5%Form 10-K (filed 2024-02-21) ↗
FY2020Dec 31, 2020510-20.9%Form 10-K (filed 2023-02-22) ↗
FY2019Dec 31, 2019646-14.8%Form 10-K (filed 2022-02-23) ↗
FY2018Dec 31, 2018758-21.5%Form 10-K (filed 2021-02-17) ↗
FY2017Dec 31, 2017965+25.3%Form 10-K (filed 2020-02-19) ↗
FY2016Dec 31, 2016771–Form 10-K (filed 2019-02-19) ↗

Cite this data

StockData. (2026). Eli Lilly Forteo (teriparatide) — U.S. revenue [legacy] ($M), annual FY2016–FY2023 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-forteo-us

See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.